News
From Engineering to Neurodegeneration: A PhD Student’s Path to Clinical Mass Spectrometry Innovation
By: Happiness E. Aigbogun | Karikari Lab Yijun Chen was a PhD student in the lab of Dr. Thomas Karikari, the Director of the Biofluid Biomarker Laboratory and the Mass Spectrometry and Single Molecule Analytics programs at the University of Pittsburgh School of...
Exploring New Frontiers in Alzheimer’s Research: Reflections from AAIC Canada
By Happiness E. Aigbogun | Karikari Lab This summer, members of our Karikari Lab team had the incredible opportunity to attend the Alzheimer’s Association International Conference (AAIC) from July 27th to July31st, 2025, held in Toronto, Canada, a city known not only...
Thomas Karikari, PhD, and Rebecca Thurston, PhD, Receive University of Pittsburgh Chancellor’s Distinguished Research Awards
Congratulations to Thomas Karikari, PhD, and Rebecca Thurston, PhD, who have each received a University of Pittsburgh Chancellor’s Distinguished Research Award! Dr. Karikari is a globally recognized expert in the discovery, method development, technical validation, and real-world implementation of blood biomarkers for Alzheimer’s disease and related neurodegenerative diseases. Dr. Thurston, an international leader in women’s health, conducts pioneering research in menopause, mental health, and cerebrovascular health in women.
Pitt Faculty Members Selected for 2025 Senior Vice Chancellor’s Research Seminar Series
elve Pitt faculty members have recently been selected to present their research for the 2025 Senior Vice Chancellor’s Research Seminar Series.
This annual lecture series, also known as the 12@12 series, focuses on research by young investigators in the biomedical sciences. Selection criteria include a nomination from a senior faculty member and involvement in a research project that fits into one of four categories: cutting-edge fundamental research
Publications by Department of Psychiatry Faculty Rank Among the Top 1% of Cited Works in 2024
Congratulations to Thomas Karikari, PhD (Assistant Professor of Psychiatry and Endowed Faculty Fellow in Peripheral Biomarkers for Brain Diseases), and Victor Villemagne, MD (Levidow-Pittsburgh Foundation Chair in Alzheimer’s Disease and Dementia Disorders and Professor of Psychiatry), who have been named…
Beyond Amyloid and Tau: A Multimarker Approach to Alzheimer’s Detection
A recent study utilized the NULISA platform to evaluate a broad panel of biomarkers, including amyloid, tau, glial, vascular, and co-pathology markers, in cognitively normal individuals to better understand early Alzheimer’s pathology. Based on the results, this multimodal approach could help redefine how we identify and predict Alzheimer’s in its preclinical stages. Learn more with study co-author Dr. Thomas Karikari, Director of the Biofluid Biomarker Laboratory at the University of Pittsburgh and an Assistant Professor of Psychiatry at the University of Pittsburgh.
Encouraging Early Intervention for Alzheimer’s in the Black Community Through an Innovative Interdisciplinary Approach
The data on Alzheimer’s disease in Black communities is stark: The risk is higher than average, but the rate of diagnosis is delayed.
To address that, several University of Pittsburgh researchers from different departments are partnering with the Allegheny County Health Department and the Black Equity Coalition (BEC) in a new interdisciplinary effort.
The Brain and Cognitive Health Equity Campaign for Allegheny County…
Two-dozen Pitt researchers made Clarivate’s annual Highly Cited list
Pittwire | November 20, 2024 |
Gloved hands place viles into a holder
Twenty-four University of Pittsburgh researchers have been named to this year’s Highly Cited Researchers list, an annual compilation of researchers whose work has made a significant impact across a broad range of disciplines. Last year, 23 Pitt researchers were included. The list…
Pitt Scientists Validate New Lab Test Platform for Blood Biomarkers of Alzheimer’s Disease
University of Pittsburgh | University of Pittsburgh scientists independently validated a new blood test platform that can simultaneously measure more than a hundred biomarkers of Alzheimer’s disease. The platform might improve clinicians’ ability to capture the multifaceted nature of Alzheimer’s pathology and streamline early…